

**IN THE CLAIMS:**

Please amend claims 3, 4, 7, 8, 10, 14, 15, 16, 17, 18, 20, 22, 27, 28, 29, as follows:

1. (Original) A method of screening a drug having a cell growth-inhibiting effect, a neovascularization-inhibiting effect, a cancer cell metastasis activity-inhibiting effect, a neuroprotective effect, an anti-allergic effect, an anti-arteriosclerotic effect and/or a Cruetzfels-Jakob disease infection-inhibiting effect, which comprises a step of qualitatively or quantitatively determining the degree of binding of a test compound to a 67 kDa laminin receptor, and, when the test compound binds to the 67 kDa laminin receptor from the test data, then judging that the test compound is a drug having a cell growth-inhibiting effect, a neovascularization-inhibiting effect, a cancer cell metastasis activity-inhibiting effect, a neuroprotective effect, an anti-allergic effect, an anti-arteriosclerotic effect and/or a Cruetzfels-Jakob disease infection-inhibiting effect.
2. (Original) The screening method as claimed in claim 1, wherein the drug has a cell growth-inhibiting effect, a neovascularization-inhibiting effect and/or a cancer cell metastasis activity-inhibiting effect.
3. (Currently Amended) A drug obtainable according to the screening method of claim 1  
~~or 2.~~
4. (Currently Amended) The drug as claimed in ~~any of claims 1 to 3, claim 1,~~ wherein the active ingredient is a compound having a galloyl group.
5. (Original) The drug as claimed in claim 4, wherein the compound is a catechin.
6. (Original) The drug as claimed in claim 5, wherein the catechin is epigallocatechin gallate.

7. (Currently Amended) The drug as claimed in ~~any of claims 3 to 6, claim 3~~, which is used for a disease capable of being prevented and/or treated owing to the cell growth-inhibiting effect, the neovascularization-inhibiting effect, the cancer cell metastasis activity-inhibiting effect, the neuroprotective effect, the anti-allergic effect, the anti-arteriosclerotic effect and/or the Creutzfels-Jakob disease infection-inhibiting effect thereof.

8. (Currently Amended) The drug as claimed in ~~any of claims 3 to 6, claim 3~~, which is used for a disease capable of being prevented and/or treated owing to the cell growth-inhibiting effect, the neovascularization-inhibiting effect and/or the cancer cell metastasis activity-inhibiting effect thereof.

9. (Original) The drug as claimed in claim 8, wherein the disease is cancer.

10. ((Currently Amended) A method for producing a pharmaceutical composition, which comprises a step of producing the drug of ~~any of claims 3 to 9, claim 3~~, by chemical synthesis, and a step of adding a pharmaceutically-acceptable carrier thereto.

11. (Original) A pharmaceutical composition obtainable according to the production method of claim 10.

12. (Original) A screening method for a drug, which comprises a step of qualitatively or quantitatively determining the degree of binding of a compound having a galloyl group and a test compound to a 67 kDa laminin receptor, and, when the degree of binding of the test compound to the 67 kDa laminin receptor is higher than that of binding of the compound having a galloyl group to the 67 kDa laminin receptor from the test data, then judging that the test compound is a drug having the same pharmacological effect as that of the compound having a galloyl group.

13. (Original) A screening method for a drug, which comprises a step of making competition between the binding of a compound having a galloyl group to a 67 kDa laminin

receptor and the binding of a test compound to the 67 kDa laminin receptor, and as a result of the competition, when the site at which the test compound has bound with the 67 kDa laminin receptor is the same as the site at which the compound having a galloyl group has bound with the 67 kDa laminin receptor, then judging the test compound is a drug having the same pharmacological effect as that of the compound having a galloyl group.

14. (Currently Amended) The screening method as claimed in claim 12 ~~or 13~~, wherein the pharmacological effect of the compound having a galloyl group is a cell growth-inhibiting effect, a neovascularization-inhibiting effect, a cancer cell metastasis activity-inhibiting effect, a neuroprotective effect, an anti-allergic effect, an anti-arteriosclerotic effect and/or a Creutzfels-Jakob disease infection-inhibiting effect.

15. (Currently Amended) The screening method as claimed in claim 12 ~~or 13~~, wherein the pharmacological effect of the compound having a galloyl group is a cell growth-inhibiting effect, a neovascularization-inhibiting effect and/or a cancer cell metastasis activity-inhibiting effect.

16. (Currently Amended) The screening method as claimed in ~~any of claims 12 to 15~~, claim 12, wherein the compound is a catechin.

17. (Currently Amended) The screening method as claimed in ~~any of claims 12 to 15~~, claim 12, wherein the catechin is epigallocatechin gallate.

18. (Currently Amended) A drug obtainable according to the screening method of ~~any of claims 12 to 17~~ claim 12.

19. (Original) The drug as claimed in claim 18, which is used for a disease capable of being prevented and/or treated owing to the cell growth-inhibiting effect, the neovascularization-inhibiting effect, the cancer cell metastasis activity-inhibiting effect, the neuroprotective effect, the anti-allergic effect, the anti-arteriosclerotic effect and/or the Creutzfels-Jakob disease infection-inhibiting effect thereof.

20. (Currently Amended) The drug as claimed in claim 18 ~~or 19~~, which is used for a disease capable of being prevented and/or treated owing to the cell growth-inhibiting effect, the neovascularization-inhibiting effect and/or the cancer cell metastasis activity-inhibiting effect thereof.

21. (Original) The drug as claimed in claim 20, wherein the disease is cancer.

22. (Currently Amended) A method for producing a pharmaceutical composition, which comprises a step of producing the drug of ~~any of claims 18 to 21, claim 18~~, by chemical synthesis, and a step of adding a pharmaceutically-acceptable carrier thereto.

23. (Original) A pharmaceutical composition obtainable according to the production method of claim 22.

24. (Original) A compound capable of binding to a 67 kDa laminin receptor at a site thereof that is the same as the site at which a compound having a galloyl group binds to the 67 kDa laminin receptor.

25. (Original) The compound as claimed in claim 24, which is a catechin.

26. (Original) The compound as claimed in claim 25, wherein the catechin is epigallocatechin gallate.

27. (Currently Amended) A cell growth inhibitor containing the compound of ~~any of claims 24 to 26, claim 24.~~

28. (Currently Amended) A neovascularization inhibitor containing the compound of ~~any of claims 24 to 26, claim 24.~~

29. (Currently Amended) A cancer cell metastasis activity inhibitor containing the compound of ~~any of claims 24 to 26, claim 24.~~

30. (Currently Amended) An anticancer agent inhibitor containing the compound of ~~any of claims 24 to 26, claim 24.~~